The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH MM 2018 | MRD negativity using deep sequencing is a major prognostic factor in myeloma
Nikhil Munshi, MD, from the Dana-Farber Cancer Institute, Boston, MA, discusses the findings of his recent MRD-focused analysis of a large randomized trial for newly diagnosed multiple myeloma (MM) patients treated with lenalidomide, bortezomib and dexamethasone. This revealed that MRD, measured using next-generation sequencing, is a major prognostic factor in MM. Dr Munshi suggests that MRD status can thus inform clinical practice, and calls for MRD to be assessed in every prospective trial. This video was recorded at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.
